DOH provided Consumer advocates with drafts of notices regarding passive enrollment in FIDA to begin fall 2014.

Selfhelp's Training Outline on Medicare Part D cites documents in an Appendix, such as lists of plans, forms, charts and tables. This Appendix is updated for the 2014 year.

Chart showing all Medicare Advantage, Medicaid Advantage, Medicaid Advantage Plus and PACE plans in NYS - IN NEW YORK CITY by borough, with number of Medicare beneficiaries enrolled in each plan.

Medicare Advantage data from Feb. 2013 - http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MCRAdvPartDEnrolData/index.html

Medicaid plan data from Mar. 2013 - monthly Medicaid Managed Care Enrollment Report - http://www.health.ny.gov/health_care/managed_care/reports/enrollment/monthly/

Chart showing all Medicare Advantage, Medicaid Advantage, Medicaid Advantage Plus and PACE plans in NYS - outside NYC by county, with number of Medicare beneficiaries enrolled in each plan.

Medicare Advantage data from Feb. 2013 - http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MCRAdvPartDEnrolData/index.html

Medicaid plan data from Mar. 2013 - monthly Medicaid Managed Care Enrollment Report

Memorandum dated Nov. 7, 2012 for Part D and MA plans to allow some out-of-network access, lift refill limits, and lift other restrictions because of public health emergency.

Extends past December 7, 2012 for enrollment for Part D and Medicare Advantage. Dated Nov. 7, 2012. See instructions in PDF>

Initial timetable for NYS plan to coordinate all Medicare and Medicaid care for all dual eligibles in NYS beginning January 2014.

Federal publication showing tips for changes in using the Planfinder tool to select Part D drug coverage.

Effective October 2010, EPIC will no longer provide supplemental coverage to pay for drugs not covered on a Part D plan formulary, unless the member and their physician first request a coverage determination by the plan, and then, if denied, filing two levels of appeal.